Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription


1 Acta Neurol Scand
2 BMC Neurol
1 Brain
9 J Autoimmun
1 J Neuroimmunol
2 J Neurol
1 Kidney Int
2 Lancet
1 Mult Scler
1 Neurologia (Engl Ed)
2 Neurology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neurol Scand

  1. SILVA GD, Castrillo BB, Apostolos-Pereira SL, Callegaro D, et al
    Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
    Acta Neurol Scand. 2022 Sep 2. doi: 10.1111/ane.13697.
    PubMed         Abstract available

    BMC Neurol

  2. YAO Y, Li X, Xu Y, Liang X, et al
    The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.
    BMC Neurol. 2022;22:323.
    PubMed         Abstract available

  3. PURAM VV, Ghazaleh D, Salari A, McCleary K, et al
    Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report.
    BMC Neurol. 2022;22:318.
    PubMed         Abstract available


  4. AL-DIWANI A, Theorell J, Damato V, Bull J, et al
    Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.
    Brain. 2022;145:2742-2754.
    PubMed         Abstract available

    J Autoimmun

  5. BEVILACQUA ROLFSEN FERREIRA DA, Pereira das Neves S, Roque Oliveira SC, Marques F, et al
    Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis.
    J Autoimmun. 2022;132:102893.
    PubMed         Abstract available

  6. MYHR KA, Zinglersen AH, Hermansen MF, Jepsen MM, et al
    Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: An echocardiographic follow-up study.
    J Autoimmun. 2022;132:102884.
    PubMed         Abstract available

  7. NING W, Xu W, Cong X, Fan H, et al
    COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman.
    J Autoimmun. 2022;132:102896.
    PubMed         Abstract available

  8. ZHANG W, Shao T, Leung PSC, Tsuneyama K, et al
    Dual B-cell targeting therapy ameliorates autoimmune cholangitis.
    J Autoimmun. 2022;132:102897.
    PubMed         Abstract available

  9. JIANG Y, Cheng Y, Ma S, Li T, et al
    Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment.
    J Autoimmun. 2022 Aug 24:102887. doi: 10.1016/j.jaut.2022.102887.
    PubMed         Abstract available

  10. JIANING W, Jingyi X, Pingting Y
    Neuropsychiatric lupus erythematosus: Focusing on autoantibodies.
    J Autoimmun. 2022 Aug 24:102892. doi: 10.1016/j.jaut.2022.102892.
    PubMed         Abstract available

  11. XIA Y, Jiang C, Yang M, Liu T, et al
    SB431542 alleviates lupus nephritis by regulating B cells and inhibiting the TLR9/TGFbeta1/PDGFB signaling.
    J Autoimmun. 2022;132:102894.
    PubMed         Abstract available

  12. RODRIGUEZ Y, Rojas M, Beltran S, Polo F, et al
    Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.
    J Autoimmun. 2022;132:102898.
    PubMed         Abstract available

  13. CHEN K, Li Y, Yang H
    Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications.
    J Autoimmun. 2022;132:102895.
    PubMed         Abstract available

    J Neuroimmunol

  14. WU H, Chen L, Zhou X, Wu Y, et al
    Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
    J Neuroimmunol. 2022;372:577955.
    PubMed         Abstract available

    J Neurol

  15. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    PubMed         Abstract available

  16. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    PubMed         Abstract available

    Kidney Int

  17. TODA E, Sawada A, Takeuchi K, Wakamatsu K, et al
    Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.
    Kidney Int. 2022 Aug 29. pii: S0085-2538(22)00687.
    PubMed         Abstract available


    Autoimmune diseases and atherothrombotic risk.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.

  19. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    PubMed         Abstract available

    Mult Scler

  20. PORTACCIO E, Amato MP
    Reliable change indices for cognitive assessment of patients with multiple sclerosis.
    Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.

    Neurologia (Engl Ed)

  21. MIRMOSAYYEB O, Shaygannejad V, Ebrahimi N, Ghoshouni H, et al
    The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis.
    Neurologia (Engl Ed). 2022 Aug 30. pii: S2173-5808(22)00090.
    PubMed         Abstract available


  22. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    PubMed         Abstract available

  23. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.